An investigational exosome-based liquid biopsy accurately detected 97% of stage 1-2 pancreatic cancers when combined with the biomarker CA 19-9, according to research presented at the American ...

The company’s pipeline of products includes the ExoDx Prostate test, the first exosome-based liquid biopsy on the market, and various discovery platforms to help solve biopharma’s biomarker ...

Collaboration aims to evaluate the potential to advance drug development with Exosome’s proprietary liquid biopsy diagnostics technology and platform. with the Breaking Science News daily newsletter ...

Liquid biopsy is a revolutionary molecular diagnostic tool that allows scientists to detect genetic abnormalities or monitor disease progression non-invasively. However, clinicians encounter several ...

Many tumors display regional heterogeneity (diverse tumor cells) that can limit the ability of a single, tissue-based biopsy to access the full molecular profile of the tumor. In contrast, liquid ...

The global liquid biopsy market is experiencing substantial growth, driven by increasing demand for non-invasive diagnostic technologies that detect molecular biomarkers using liquid samples, thus ...